BIO Asia–Taiwan 2025 亞洲生技大會

Building the Future of
Cell & Gene Therapies

From July 23 to 27, we invite you to join us at BIO Asia–Taiwan 2025, to explore how technical, regulatory, and strategic forces are driving next-generation manufacturing for advanced therapies.

Featured speakers include Ann Lee, Chief Technical Officer at Prime Medicine, and Snehal Patel, Executive Vice President and CTO of Sana Biotechnology—both of whom are leading efforts to develop scalable and clinically aligned production platforms. Matthew Hewitt, Vice President and CTO of the Manufacturing Business Division at Charles River Laboratories, will examine how manufacturing must evolve to balance technological speed with regulatory compliance. Jeffrey Chou, Senior Vice President of Clinical Science at Iovance Biotherapeutics, will offer a clinical perspective on the complexities of late-stage therapeutic production. The session will be moderated by David Chang, CEO of Taiwan Bio-Manufacturing Corporation (TBMC).

Come to this important session and examine how gene and cell therapy manufacturing is shaping the future of medicine.

Early Bird: Register by 6/20 & Save $275